Fulgent Genetics, Inc. (FLGT)
Automate Your Wheel Strategy on FLGT
With Tiblio's Option Bot, you can configure your own wheel strategy including FLGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FLGT
- Rev/Share 9.4852
- Book/Share 36.4157
- PB 0.5361
- Debt/Equity 0.0068
- CurrentRatio 6.3231
- ROIC -0.0475
- MktCap 596694560.0
- FreeCF/Share -1.0254
- PFCF -18.8744
- PE -14.8202
- Debt/Assets 0.0064
- DivYield 0
- ROE -0.036
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulgent Genetics, Inc. (FLGT) And Encourages Investors to Connect
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Stockholders to Inquire about Securities Investigation
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Stockholders to Learn More About the Investigation
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: May 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) on behalf of Fulgent stockholders. Our investigation concerns whether Fulgent has violated the federal securities laws and/or engaged in other unlawful business practices.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Published: May 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , May 19, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces its investigation of potential breaches of fiduciary duty by the Board of Directors and senior management of Fulgent Genetics, Inc. (NASDAQ: FLGT). Key Details: Subject of Investigation: Whether Fulgent Genetics and certain officers/directors violated their fiduciary duty to shareholders.
Read More
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Read More
Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ago.
Read More
Stock Picks From Seeking Alpha's March 2025 New Analysts
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Neutral
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.
Read More
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a significant undervaluation. However, nothing is cheap for no reason; the company is not making money and won't for a while.
Read More
Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Read More
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9 million, or ($0.19) per share Non-GAAP income.
Read More
About Fulgent Genetics, Inc. (FLGT)
- IPO Date 2016-09-29
- Website https://www.fulgentgenetics.com
- Industry Medical - Diagnostics & Research
- CEO Ming Hsieh
- Employees 1313